Factors associated with RA biologic or JAK inhibitor treatment switch (N = 60,596 patients analyzed).
| Adjusted* OR (95% CI) | |
|---|---|
| MBDA score | |
| Low (referent) | 1.0 |
| Moderate, 30–44 | 1.51 (1.35–1.69) |
| High, > 44 | 2.62 (2.26–3.05) |
| Age (5-yr increments) | 0.91 (0.89–0.92) |
| Male sex (female referent) | 0.85 (0.79–0.91) |
| Low income** | 1.16 (1.07–1.25) |
| Race (white referent) | |
| Black | 0.76 (0.69–0.84) |
| Other | 0.93 (0.86–1.01) |
| Fibromyalgia | 1.13 (1.05–1.21) |
| Charlson comorbidity index | |
| 0 | 1.0 (referent) |
| 1 | 1.24 (1.10–1.40) |
| 2 | 1.25 (1.10–1.42) |
| 3+ | 1.38 (1.12–1.47) |
| Recent hospitalization | 1.18 (1.10–1.28) |
| RA medications | |
| TNFi biologic | 0.60 (0.52–0.68) |
| Non-TNFi biologic | 0.57 (0.47–0.68) |
| MTX | 1.09 (1.02–1.16) |
| HCQ/SSZ/LEF | 1.01 (0.95–1.08) |
| Glucocorticoid | 1.40 (1.33–1.48) |
↵* Also adjusted for diabetes, chronic pulmonary disease, obesity, and being disabled, none of which were significant, and for physician clustering (OR 1.19, 95% CI 1.06–1.34).
↵** Reflected by state buy-in for Medicare premiums. RA: rheumatoid arthritis; JAK: Janus kinase; MBDA: multibiomarker disease activity; TNFi: tumor necrosis factor inhibitor; MTX: methotrexate; HCQ: hydroxychloroquine; SSZ: sulfasalazine; LEF: leflunomide.